rgp120 HIV-1 IIIB (CHO)

$655.00
SKU: 1041

Product Specifications: 

Item# 1041-2: Recombinant HIV-1 IIIB Glycoprotein gp120 (CHO) 

 

Concentration: See vial 

Diluent: PBS

Purity: >95%

Stabilizer: None

Preservative: None

Storage: -75°C

Physical State: Frozen

Liquid Stability: At least 6 months at -75°C.

Applications: In-Vitro Diagnostics, CD4 Binding, T-Cell Activation.

Description: Full length Recombinant HIV-1 IIIB gp120 glycoprotein produced in the CHO Expression System.

Purification: This protein is purified by immunoaffinity chromatography to >95% purity as determined by SDS-PAGE, reduced.

Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and human serum polyclonal antibodies in ELISA and Western ELISA.

Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti-gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells.

Application and Instructions for use

Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 100ng of solid phase protein under standard ELISA conditions.

Item#: 1041-P Peroxidase-Conjugated rgp120 HIV-1 IIIB

Application: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies. 

Safety Study of rgp120/HIV-1IIIB Vaccine

Recent evidence suggests that gp120 is the HIV-1 protein with the greatest potential as a vaccine against HIV-1 infection. The gp120 envelope protein may be produced by recombinant DNA technology, and studies have shown that the vaccine is capable of eliciting neutralizing antibody activity in both rodents and nonhuman primate species.

Official Study Title: A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

Disease: HIV Infections

Treatment: Biological: rgp120/HIV-1IIIB and Biological: rgp120/HIV-1MN 

ORIGINAL DESIGN: Twenty-eight subjects will be randomized to receive 100 or 300 mcg rgp120/HIV-1IIIB vaccine (gp120 vaccine) or matching placebo. For each dose level, 10 subjects will receive vaccine and four subjects will receive matching placebo. Injections are given intramuscularly at 0, 4, and 32 weeks. Each subject receiving treatment at the lower dose level must be monitored for unacceptable toxicity for at least 2 weeks following the initial immunization before his or her second dose is administered and before treatment at the higher dose level begins. Subjects are followed for at least 12 months.

AMENDED 11/17/93: Selected subjects from VEU 006 or VEU 006 Rollover study will receive two injections of MN rgp120 vaccine, administered 28 days apart beginning 10-16 months after their last injection. Eight additional clinic visits will be required. Subjects are followed for at least 6 months.

CHO- expressed HIV-1IIIB rgp120 (2.5 μg) and biotinylated cyclic V2-TH023 peptide (1 μg and 5 μg) were incubated with RPMI8866 cells